The largest database of trusted experimental protocols

Anti mouse cd8α

Manufactured by BioXCell
Sourced in United States

Anti-mouse CD8α is a laboratory reagent used to detect and quantify CD8α-positive cells in mouse samples. It is a monoclonal antibody that binds specifically to the CD8α subunit, which is expressed on the surface of cytotoxic T cells and a subset of natural killer cells. This product can be used in flow cytometry, immunohistochemistry, and other immunoassays to study the immune system and its response to various stimuli.

Automatically generated - may contain errors

5 protocols using anti mouse cd8α

1

T-cell Depletion in BiCyclA Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+ and CD8+ T cells were individually depleted to investigate the T-cell dependency of the BiCyclA treatment effect. Mice were injected intraperitoneally with 200 µL of sterile saline with 100 µg of antibody every 3 days, beginning 3 days after tumor inoculation. CD4+ T cells were depleted with anti-mouse CD4 (Clone GK1.5, BioXcell, Catalog # BE0003-1). CD8+ T cells were depleted with anti-mouse CD8α (Clone 2.43, BioXcell, Catalog # BE0061). As a control, one group of mice were given rat IgG2b isotype control, anti-keyhole limpet hemocyanin (Clone LTF-2, BioXcell, Catalog # BE0090).
+ Open protocol
+ Expand
2

Prostate Cancer Immunotherapy Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
At the age of four months, a combination of anti-mouse PD1 (Bio X Cell, BE0146) and anti-mouse CTLA-4 (Bio X Cell, BE0131) was administered at a dose of 5 μg of each antibody per gram of mouse, both antibodies in 100 μL. To eliminate CD8 T cells, anti-mouse CD8α (Bio X Cell, BE0061) was administered at a dose of 100 μg per mouse. As control treatment, a combination of rat IgG2a isotype control (Bio X Cell, BE0089) and polyclonal Syrian hamster IgG (Bio X Cell, BE0087) was used as a control at the same dose. All treatments were administered by intraperitoneal injection every three days for eighteen days. Mice were weighed every three days to discard treatment toxicity. The in vivo response to immune checkpoint blockade or CD8 T cells inhibition was evaluated by measuring each prostate lobe volume one week after the treatment regime was completed.
+ Open protocol
+ Expand
3

Tumor Immunotherapy Combination Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
All DsiRNAs were synthesized by Integrated DNA Technologies (IDT, Coralville, IA). Primer and probe oligonucleotides used in real-time qPCR detection were synthesized by IDT or Life Technologies (Carlsbad, CA). Monoclonal antibodies (anti-mouse PD-1, anti-mouse CTLA-4, and anti-mouse CD8α) were purchased from Bio X Cell (Lebanon, NH). Tumor dissociation kit and Smart Strainers used to make single-cell suspension were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Monoclonal antibodies used for flow cytometry were purchased from BioLegend (San Diego, CA). DCR-BCAT and Placebo LNPs were prepared as previously described.19 (link) Anti PD-1 antibody, anti-CTLA-4 antibodies, and anti-CD8a antibodies were diluted in PBS and administered intraperitoneally. DCR-BCAT and DCR-Placebo (LNP with chemistry-matched, scrambled CTNNB1 DsiRNA) were given intravenously. LGK-974 was purchased from Selleckchem.com (Houston, TX). LGK-974 was dissolved in DMSO (2%) and Corn Oil (solvents added individually and in order) and was administered orally.
+ Open protocol
+ Expand
4

CD8+ T Cell Depletion in MC38-luc Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD8 + T cells were depleted from MC38-luc orthotopic tumor-bearing mice by injecting 200 µg/100 microliter (µL) PBS anti-mouse CD8α (BioxCell, Lebanon NH, USA) or IgG control s.c. every third day from days 5–19 and monitored by IVIS (Perkin Elmer).
+ Open protocol
+ Expand
5

Photodynamic Therapy Agents Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Meso-tetraphenyl chlorin disulphonate (TPCS2a) was obtained from PCI Biotech AS (Oslo Norway) VEGF121/rGel, from now indicated as VEGF121/rGel, was produced as previously described (9 (link)). Hypericin was obtained from Sigma-Aldrich (St Louis, MO, USA) while Anti-mouse CTLA-4 (CD152) and anti-mouse CD8α were obtained from BioxCell (Lebanon, NH, USA). In vitro TPCS2a light exposure was performed with a LumiSource TM lamp (PCI Biotech AS) while TPCS2ain vivo light exposure was done with a 652nm diode laser (CeramOptec GmbH, Bonn, Germany). For Hypericin yellow irradiations were carried out with a custom-made lamp equipped with an array of 1W LEDs (18 (link)). The irradiance was measured to 0.9 mW cm−2 by a photodetector PH100-SiUV coupled to a calibrated optic power meter Gentec-EO SOLO2 (Gentec-EO, Quebec, Canada). The spectrum of the yellow lamp was measured by an irradiance-calibrated AvaSpec-2048x14-SPU2 FiberOptic Spectrometer (Avantes, Apeldoorn, The Netherlands) and peaked at approximately 590 nm. For more information see Supplementary Material.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!